SANA: Gene-edited islet therapy for type 1 diabetes nears clinical trial, with CAR T data expected in 2027
The discussion highlighted progress toward a gene-edited, stem cell-derived islet therapy for type 1 diabetes, with IND clearance and a phase I trial expected this year. The in vivo CAR T platform is advancing, with clinical data anticipated in 2027. Strategic partnerships, manufacturing scalabilit…
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.